Title: Surge in EG.5 Coronavirus Subvariant Raises Concerns, but Current Measures Remain Effective
Infections and hospitalizations associated with the EG.5 “Eris” coronavirus, a subvariant of the Omicron lineage, have been rapidly increasing across the United States, Europe, and Asia. The World Health Organization (WHO) has now classified EG.5 as a “variant of interest” due to its potential for increased transmissibility and severity, although no evidence of increased disease severity has been found thus far.
With EG.5 spreading to over 50 countries, it has become the most common and fastest-growing subvariant responsible for approximately 17% of current COVID-19 cases in the US. Despite this surge, it is essential to note that COVID-related hospitalizations have risen by over 40% from recent lows in June but remain more than 90% lower than the peak levels experienced during the January 2022 Omicron outbreak.
Recent data analyses have shown striking increases in both the amount of virus detected in wastewater samples and the number of prescriptions for the COVID treatment Paxlovid. These developments reflect the heightened activity of EG.5 and indicate the urgency to tackle its spread effectively.
Taking swift action, vaccine manufacturers including Pfizer, Moderna, and Novavax have developed new versions of their vaccines targeting the Omicron sublineage XBB.1.5, which bears similarities to EG.5 with the addition of one mutation. These updated vaccines are projected to be widely available in the US by the third or fourth week of September, offering renewed protection against emerging subvariants.
Dr. Mandy Cohen, the Director of the Centers for Disease Control and Prevention (CDC), has reassured the public that currently available vaccines, medications, and tests remain effective against the evolving virus. Heightening vigilance and adhering to preventive measures such as vaccination, wearing masks, and practicing social distancing can still help limit the transmission of EG.5 and its variants.
As the world grapples with the surge of EG.5 infections, continuous monitoring and research will be crucial to counteract any potential threats posed by this emerging subvariant. The global community must remain vigilant and adaptable to ensure the ongoing effectiveness of existing measures while preparing for any future developments in the fight against COVID-19.
“Travel aficionado. Incurable bacon specialist. Tv evangelist. Wannabe internet enthusiast. Typical creator.”